Casi Pharmaceuticals (CASI) said Thursday its board received an updated non-binding proposal from Chairman and CEO Wei-Wu He to acquire its entire business operations in China for $20 million.
The proposal includes the acquisition of all of the company's license-in, distribution, and related rights in Asia, excluding Japan, related to certain of its pipeline products. The latest offer updates a preliminary non-binding proposal that He submitted in June 2024, Casi said.
The company's shares were 11.5% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.